HOME >> BIOLOGY >> NEWS
Record ozone loss during 2006 over South Pole

is season, polar stratospheric clouds are formed that contain chlorine.

As the polar spring arrives, the combination of returning sunlight and the presence of polar stratospheric clouds leads to splitting of chlorine compounds into highly ozone-reactive radicals that break ozone down into individual oxygen molecules. A single molecule of chlorine has the potential to break down thousands of molecules of ozone.

The ozone hole, first recognised in 1985, typically persists until November or December, when the winds surrounding the South Pole (polar vortex) weaken, and ozone-poor air inside the vortex is mixed with ozone-rich air outside it.

Envisat, the largest Earth observation satellite ever built, can localise ozone depletion and track its changes, enabling the rapid estimation of UV radiation as well as providing forecasting. The three atmospheric instruments aboard Envisat are the Scanning Imaging Absorption Spectrometer for Atmospheric Cartography (SCIAMACHY), the global ozone monitoring by occultation of stars (GOMOS) sensor and the Michelson interferometer for passive atmospheric sounding (MIPAS).

In the framework of GMES (Global Monitoring of the Environment and Security), ESA has backed a project named TEMIS (Tropospheric Emission Monitoring Internet Service) that provides operational ozone and UV radiation monitoring based on SCIAMACHY and GOME-1 data. The ozone-monitoring data provided by these instruments span a time period of 11 years, which will be extended by the upcoming MetOp satellite series.

The first MetOp satellite in the series of three is scheduled to be launched in 2006 and will assist climate researchers in monitoring ozone levels and other atmospheric parameters. MetOp Europe's first polar-orbiting satellite and a mission dedicated to operational meteorology will include a next-generation ozone-monitoring instrument called GOME-2, intended to guarantee continuity of observation of this
'"/>

Contact: Mariangela D'Acunto
mariangela.dacunto@esa.int
39-069-418-0856
European Space Agency
2-Oct-2006


Page: 1 2 3

Related biology news :

1. Record number of abstracts submitted for largest scientific congress devoted to osteoporosis
2. Record bonefish
3. Satellite instrument helps tackle mysteries of ozone-eating clouds
4. Overseas NOx could be boosting ozone levels in US
5. Study finds no safe level for ozone
6. New window into ancient ozone holes
7. NASAs aura satellite sheds new light on air quality and ozone hole
8. Study links ozone, mortality in urban areas
9. Ground-level ozone linked to increased mortality
10. Regulating alternative splicing during neural development
11. Burning fat and carbohydrate during exercise

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Record ozone loss during over South Pole

(Date:3/24/2015)... Mar. 24, 2015 Research and Markets ... "Global Iris Recognition Market 2015-2019" report to ... Iris Recognition market to grow at a CAGR of ... report covers the present scenario and the growth prospects ... 2015-2019. To calculate the market size, the report considers ...
(Date:3/24/2015)... Fla. , March 24, 2015   ... management solutions, today announced that its U.are.U ® ... accessory retailer Goorin Bros . to achieve ... biometrics-based solution secures access to the POS terminal, ... increased risk of data breaches. ...
(Date:3/23/2015)... , March 23, 2015  In the 2014 fiscal ... case conviction losses. This figure accounts for a fraction ... to The Nilson Report, exceeds $11 billion globally. The ... after a crime has occurred. Investor Mark Saint ... expert Joe Paolella partnered to administer the ...
Breaking Biology News(10 mins):Global Iris Recognition Market 2015-2019 with 3M Cogent, Bioenable Technologies, Cross Match Technology, Iris ID Systems & Safran Dominating 2Crossmatch Fingerprint Readers Help Retailer Prevent Data Breaches at Point-of-Sale 2Polygraph Test Now Used to Protect Investors From Fraud 2Polygraph Test Now Used to Protect Investors From Fraud 3
(Date:3/30/2015)... -- CASI Pharmaceuticals, Inc. (Nasdaq: CASI ), a ... of innovative therapeutics addressing cancer and other unmet medical ... on China , announced today that ... the Company,s application to conduct a Phase 2 global ... for its proprietary drug candidate ENMD-2076.  ...
(Date:3/30/2015)... 30, 2015    Intrexon Corporation (NYSE: ... and Merck Serono, the biopharmaceutical business of Merck ... announced an exclusive strategic collaboration and license agreement ... (CAR-T) cancer therapies. This collaboration advances Merck Serono,s ... modulate the immune system,s natural ability to fight ...
(Date:3/30/2015)... and BELLINGHAM, Washington, USA (PRWEB) March 29, 2015 ... in Europe and the United States and plenary talks ... planned for SPIE Optics + Optoelectronics next ... over 700 technical presentations in 17 conferences alongside a ... for optics and photonics , the event will run ...
(Date:3/30/2015)... 30, 2015  Naldemedine, an investigational peripherally acting ... & Co., Ltd., met its primary and secondary ... for the treatment of opioid-induced constipation (OIC) in ... therapy. Study results showed that naldemedine (0.2 mg ... frequency of spontaneous bowel movement (SBM) compared with ...
Breaking Biology Technology:CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 2CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 3CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 4CASI Pharmaceuticals Receives Approval From CFDA For Phase 2 Clinical Trial In China With ENMD-2076 For Ovarian Clear Cell Carcinoma 5Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 2Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 3Intrexon and Merck Serono Announce Agreement for the Development and Commercialization of CAR-T Therapy 4Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 2Laser Energy Advances Among Reports Set for SPIE Optics + Optoelectronics 3Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 2Shionogi & Co., Ltd. Announces That Naldemedine Meets Primary Endpoint In A Phase 3 Study For The Treatment Of Opioid-Induced Constipation 3
Cached News: